Drug company gives ofatumumab update
Posted: Wed Mar 09, 2016 2:59 am
Biotech firm Genmab has announced an update on development plans for ofatumumab in autoimmune indications focusing on relapsing multiple sclerosis following the transfer of the rights to ofatumumab from GlaxoSmithKline (GSK) to Novartis at the end of 2015...Read more - http://www.ms-uk.org/MSnews